High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1619-7089
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics ; day:5 ; month:7 ; year:2021 ; pages:1-5
European journal of nuclear medicine and molecular imaging ; (5.7.2021), 1-5

Urheber
Kesch, Claudia
Yirga, Leubet
Dendl, Katharina
Handke, Analena
Darr, Christopher
Krafft, Ulrich
Radtke, Jan Philipp
Tschirdewahn, Stephan
Szarvas, Tibor
Fazli, Ladan
Gleave, Martin
Giesel, Frederik L.
Haberkorn, Uwe
Hadaschik, Boris
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1007/s00259-021-05423-y
URN
urn:nbn:de:101:1-2021102521444030058880
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:27 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Kesch, Claudia
  • Yirga, Leubet
  • Dendl, Katharina
  • Handke, Analena
  • Darr, Christopher
  • Krafft, Ulrich
  • Radtke, Jan Philipp
  • Tschirdewahn, Stephan
  • Szarvas, Tibor
  • Fazli, Ladan
  • Gleave, Martin
  • Giesel, Frederik L.
  • Haberkorn, Uwe
  • Hadaschik, Boris
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Evolving Personalized Therapy for Castration-Resistant Prostate Cancer

Evolving Personalized Therapy for Castration-Resistant Prostate Cancer

Targeting molecular resistance in castration-resistant prostate cancer

Targeting molecular resistance in castration-resistant prostate cancer

Osteoclasts directly influence castration-resistant prostate cancer cells

Osteoclasts directly influence castration-resistant prostate cancer cells

Effect of simvastatin on castration-resistant prostate cancer cells

Effect of simvastatin on castration-resistant prostate cancer cells

Ureter metastatic castration-resistant prostate cancer: a case report

Ureter metastatic castration-resistant prostate cancer: a case report

Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends

Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends

Ailanthone: a new potential drug for castration-resistant prostate cancer

Ailanthone: a new potential drug for castration-resistant prostate cancer

Chromogranin A: a useful biomarker in castration-resistant prostate cancer

Chromogranin A: a useful biomarker in castration-resistant prostate cancer

Physician preferences for non-metastatic castration-resistant prostate cancer treatment

Physician preferences for non-metastatic castration-resistant prostate cancer treatment

Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches

Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches

Targeting the adaptive molecular landscape of castration‐resistant prostate cancer

Targeting the adaptive molecular landscape of castration‐resistant prostate cancer

Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC)

Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC)

Verbundene Objekte